Cartesian Therapeutics Company Insiders

Cartesian Therapeutics Management Team Effectiveness

The company has return on total asset (ROA) of (0.1267) % which means that it has lost $0.1267 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (70.2926) %, meaning that it created substantial loss on money invested by shareholders. Cartesian Therapeutics' management efficiency ratios could be used to measure how well Cartesian Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Equity is expected to grow to 10.76, whereas Return On Tangible Assets are forecasted to decline to (0.40). At present, Cartesian Therapeutics' Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 263.7 M, whereas Non Currrent Assets Other are forecasted to decline to about 1.3 M. The current year's Common Stock Shares Outstanding is expected to grow to about 28.6 M. The current year's Net Income Applicable To Common Shares is expected to grow to about 42.7 MCartesian Therapeutics holds a total of 26 Million outstanding shares. Cartesian Therapeutics shows majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 60.9 percent of Cartesian Therapeutics outstanding shares that are owned by insiders signifies that they have been buying or selling the stock in recent months in anticipation of some upcoming event. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it. Some institutional investors establish a significant position in stocks such as Cartesian Therapeutics in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Cartesian Therapeutics, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.

Cartesian Therapeutics Workforce Comparison

Cartesian Therapeutics Insider Trading

Cartesian Therapeutics Notable Stakeholders

String symbol = request.getParameter("s");

The success or failure of an entity such as Cartesian Therapeutics often depends on how effective the management is. Cartesian Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Cartesian management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Cartesian management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.

Please note, the presentation of Cartesian Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Cartesian Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Cartesian Therapeutics' management manipulating its earnings.

When running Cartesian Therapeutics' price analysis, check to measure Cartesian Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cartesian Therapeutics is operating at the current time. Most of Cartesian Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cartesian Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cartesian Therapeutics' price. Additionally, you may evaluate how the addition of Cartesian Therapeutics to your portfolios can decrease your overall portfolio volatility.